Logo image of HIVE

HIVE DIGITAL TECHNOLOGIES LT (HIVE) Stock Fundamental Analysis

NASDAQ:HIVE - Nasdaq - CA4339211035 - Common Stock - Currency: USD

1.7835  +0.11 (+6.8%)

Fundamental Rating

4

Overall HIVE gets a fundamental rating of 4 out of 10. We evaluated HIVE against 284 industry peers in the Software industry. While HIVE seems to be doing ok healthwise, there are quite some concerns on its profitability. HIVE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HIVE had negative earnings in the past year.
HIVE had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: HIVE reported negative net income in multiple years.
Each year in the past 5 years HIVE had a positive operating cash flow.
HIVE Yearly Net Income VS EBIT VS OCF VS FCFHIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.38%, HIVE is in the better half of the industry, outperforming 61.62% of the companies in the same industry.
The Return On Equity of HIVE (-1.52%) is better than 64.08% of its industry peers.
Industry RankSector Rank
ROA -1.38%
ROE -1.52%
ROIC N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE Yearly ROA, ROE, ROICHIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE Yearly Profit, Operating, Gross MarginsHIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HIVE has been increased compared to 1 year ago.
The number of shares outstanding for HIVE has been increased compared to 5 years ago.
Compared to 1 year ago, HIVE has an improved debt to assets ratio.
HIVE Yearly Shares OutstandingHIVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HIVE Yearly Total Debt VS Total AssetsHIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

HIVE has an Altman-Z score of 3.76. This indicates that HIVE is financially healthy and has little risk of bankruptcy at the moment.
HIVE's Altman-Z score of 3.76 is fine compared to the rest of the industry. HIVE outperforms 64.44% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that HIVE is not too dependend on debt financing.
HIVE has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 3.76
ROIC/WACCN/A
WACC7.45%
HIVE Yearly LT Debt VS Equity VS FCFHIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.41 indicates that HIVE has no problem at all paying its short term obligations.
HIVE has a better Current ratio (10.41) than 94.37% of its industry peers.
HIVE has a Quick Ratio of 10.41. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HIVE (10.41) is better than 94.37% of its industry peers.
Industry RankSector Rank
Current Ratio 10.41
Quick Ratio 10.41
HIVE Yearly Current Assets VS Current LiabilitesHIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

HIVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.45%, which is quite impressive.
The Revenue has grown by 26.29% in the past year. This is a very strong growth!
The Revenue has been growing by 29.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)26.29%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%

3.2 Future

The Earnings Per Share is expected to grow by 41.15% on average over the next years. This is a very strong growth
Based on estimates for the next years, HIVE will show a very strong growth in Revenue. The Revenue will grow by 42.54% on average per year.
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HIVE Yearly Revenue VS EstimatesHIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
HIVE Yearly EPS VS EstimatesHIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

HIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 66.21 indicates a quite expensive valuation of HIVE.
HIVE's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 21.27. HIVE is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 66.21
HIVE Price Earnings VS Forward Price EarningsHIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -19.63
HIVE Per share dataHIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HIVE's earnings are expected to grow with 41.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.28%
EPS Next 3Y41.15%

More info and screens

0

5. Dividend

5.1 Amount

HIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

NASDAQ:HIVE (6/24/2025, 11:06:08 AM)

1.7835

+0.11 (+6.8%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)06-23 2025-06-23/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners17.39%
Inst Owner Change-7.22%
Ins Owners0.28%
Ins Owner Change0%
Market Cap322.60M
Analysts80
Price Target5.17 (189.88%)
Short Float %6.26%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.43%
Min EPS beat(2)43.42%
Max EPS beat(2)109.43%
EPS beat(4)4
Avg EPS beat(4)73.63%
Min EPS beat(4)43.42%
Max EPS beat(4)109.43%
EPS beat(8)6
Avg EPS beat(8)43.71%
EPS beat(12)7
Avg EPS beat(12)-161.22%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.98%
Min Revenue beat(2)-8.08%
Max Revenue beat(2)6.13%
Revenue beat(4)3
Avg Revenue beat(4)5.1%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)17.08%
Revenue beat(8)6
Avg Revenue beat(8)4.45%
Revenue beat(12)9
Avg Revenue beat(12)18.22%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.64%
PT rev (3m)-8.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)0%
EPS NY rev (3m)26.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 66.21
P/S 2.67
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA -19.63
EPS(TTM)-0.03
EYN/A
EPS(NY)0.03
Fwd EY1.51%
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.67
BVpS2.4
TBVpS2.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.38%
ROE -1.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA 1.22
Cap/Depr 126.51%
Cap/Sales 68.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.41
Quick Ratio 10.41
Altman-Z 3.76
F-Score3
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)132.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.57%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue 1Y (TTM)26.29%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%
EBIT growth 1Y-12.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year181.18%
EBIT Next 3Y78.28%
EBIT Next 5Y52.68%
FCF growth 1Y-59.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-169.13%
OCF growth 3Y-17.04%
OCF growth 5YN/A